Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, UK.
Ann Endocrinol (Paris). 2012 Apr;73(2):79-80. doi: 10.1016/j.ando.2012.03.039. Epub 2012 Apr 20.
Reliable epidemiological data on pituitary adenomas (PAs) are of major importance for estimating the burden on the Health Care System and for designing optimal resource distribution for clinical care and for research activities. Cross-sectional studies from Switzerland, Belgium and the UK have shown that PAs have a prevalence of 78 to 94 cases/100,000 inhabitants (three to five times higher than previously thought). Furthermore, data from Northern Finland show an overall standardized incidence rate of 4 per 100,000 with the incidentally discovered ones demonstrating an increase. The enhanced awareness of pituitary disease and the recent advances in the diagnostic technologies have contributed to the earlier recognition of PAs. Studies from diverse populations and of larger sample size are needed to expand our insight on the epidemiology of PAs.
对于评估医疗保健系统的负担以及为临床护理和研究活动分配最佳资源而言,可靠的垂体腺瘤 (PAs) 流行病学数据至关重要。来自瑞士、比利时和英国的横断面研究表明,PAs 的患病率为每 100,000 名居民中有 78 至 94 例(比之前认为的高出三到五倍)。此外,来自芬兰北部的数据显示,总体标准化发病率为每 100,000 人 4 例,其中偶然发现的发病率有所增加。对垂体疾病的认识提高以及诊断技术的最新进展有助于更早地发现 PAs。需要来自不同人群和更大样本量的研究来扩展我们对 PAs 流行病学的了解。